Spots Global Cancer Trial Database for galunisertib
Every month we try and update this database with for galunisertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
A Study of Galunisertib on the Immune System in Participants With Cancer | NCT02304419 | Neoplasm | Galunisertib | 18 Years - | Eli Lilly and Company | |
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | NCT02423343 | Solid Tumor Non-Small Cell ... Hepatocellular ... | Galunisertib Nivolumab | 18 Years - | Eli Lilly and Company | |
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | NCT01373164 | Neoplasms Neoplasm Metast... Pancreatic Canc... | Galunisertib Gemcitabine Placebo | 18 Years - | Eli Lilly and Company | |
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | NCT02734160 | Metastatic Panc... | Galunisertib Durvalumab | 18 Years - | Eli Lilly and Company | |
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | NCT03206177 | Carcinosarcoma,... | Galunisertib Paclitaxel Carboplatin | 18 Years - 99 Years | University of Oklahoma | |
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer | NCT03470350 | Colorectal Canc... | Galunisertib | 18 Years - | The Netherlands Cancer Institute | |
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer | NCT03470350 | Colorectal Canc... | Galunisertib | 18 Years - | The Netherlands Cancer Institute |